Tenecteplase or Alteplase Better in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion: A Single Center Observational Study

特奈特普酶 医学 溶栓 纤溶剂 优势比 组织纤溶酶原激活剂 冲程(发动机) 单中心 瑞替普酶 内科学 心脏病学 外科 麻醉 心肌梗塞 机械工程 工程类
作者
Agnete Teivane,Kristaps Jurjāns,Jānis Vētra,Jekaterina Grigorjeva,Karlis Kupcs,Rytis Masiliūnas,Evija Miglāne
出处
期刊:Medicina-lithuania [MDPI AG]
卷期号:58 (9): 1169-1169
标识
DOI:10.3390/medicina58091169
摘要

Background and Objectives: The study aimed to investigate the efficacy of intravenous thrombolysis with Tenecteplase before thrombectomy for acute ischemic stroke (AIS) patients compared with previous results using Alteplase. Previous trials for Tenecteplase have indicated an increased incidence of vascular reperfusion. In April 2021, we started to primarily give Tenecteplase to patients eligible to undergo thrombectomy. Materials and Methods: In this retrospective observational single-center non-randomized study, we analyzed directly admitted patients with AIS who had occlusion of the internal carotid, middle cerebral, or basilar artery and who underwent thrombectomy, as well as the recanalization rate for these patients at the first angiographic assessment (mTICI score 2b-3), and complications. Results: We included 184 patients (demographic characteristics did not differ between Tenecteplase and Alteplase groups (mean age 68.4 vs. 73.0 years; female sex 53.3% vs. 51.1%, NIHSS 14 (IQR 4-26) vs. 15 (2-31). Forty-five patients received Tenecteplase and 139 Alteplase before endovascular treatment (EVT). Pre-EVT (endovascular treatment) recanalization was more likely to occur with Tenecteplase rather than Alteplase (22.2% vs. 8.6%, p = 0.02). Successful reperfusion (mTICI 2b-3) after EVT was achieved in 155 patients (42 (93.4%) vs. 113 (81.3), p = 0.07). Hemorrhagic imbibition occurred in 15 (33.3%) Tenecteplase-treated patients compared with 39 (28.1%) Alteplase-treated patients (p = 0.5). Patients treated with Tenecteplase had higher odds of excellent functional outcome than Alteplase-treated patients (Tenecteplase 48.6% vs. Alteplase 26.1%; OR 0.37 (95% CI 0.17-0.81), p = 0.01). Conclusions: Tenecteplase (25 mg/kg) could have superior clinical efficacy over Alteplase for AIS patients with large-vessel occlusion (LVO), administered before EVT. The improvement in reperfusion rate and the better excellent functional outcome could come without an increased safety concern.

科研通智能强力驱动
Strongly Powered by AbleSci AI

祝大家在新的一年里科研腾飞
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
嘻嘻完成签到,获得积分20
3秒前
苏紫梗桔完成签到,获得积分10
4秒前
ll发布了新的文献求助10
6秒前
关我屁事完成签到 ,获得积分10
8秒前
金宁完成签到,获得积分10
10秒前
miaomliu完成签到,获得积分10
13秒前
乐乐应助裘山彤采纳,获得10
17秒前
喻槿发布了新的文献求助10
18秒前
29秒前
29秒前
喻槿完成签到,获得积分10
34秒前
qiao发布了新的文献求助10
34秒前
英俊的铭应助喻槿采纳,获得10
39秒前
隐形曼青应助lcr采纳,获得10
40秒前
41秒前
43秒前
43秒前
43秒前
44秒前
44秒前
44秒前
44秒前
44秒前
44秒前
44秒前
在水一方应助科研通管家采纳,获得10
44秒前
英俊的铭应助科研通管家采纳,获得10
45秒前
45秒前
kiki完成签到,获得积分10
46秒前
魏头头发布了新的文献求助10
47秒前
辣目童子完成签到 ,获得积分10
50秒前
51秒前
Lucycomplex完成签到,获得积分10
53秒前
程昱发布了新的文献求助10
58秒前
韦雪莲完成签到 ,获得积分10
1分钟前
魏头头完成签到 ,获得积分10
1分钟前
katata完成签到 ,获得积分10
1分钟前
小新完成签到 ,获得积分10
1分钟前
传奇3应助xdc采纳,获得10
1分钟前
务实笑柳完成签到 ,获得积分10
1分钟前
高分求助中
Yangtze Reminiscences. Some Notes And Recollections Of Service With The China Navigation Company Ltd., 1925-1939 800
Common Foundations of American and East Asian Modernisation: From Alexander Hamilton to Junichero Koizumi 600
Signals, Systems, and Signal Processing 510
Discrete-Time Signals and Systems 510
T/SNFSOC 0002—2025 独居石精矿碱法冶炼工艺技术标准 300
The Impact of Lease Accounting Standards on Lending and Investment Decisions 250
The Linearization Handbook for MILP Optimization: Modeling Tricks and Patterns for Practitioners (MILP Optimization Handbooks) 200
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5852126
求助须知:如何正确求助?哪些是违规求助? 6276113
关于积分的说明 15627658
捐赠科研通 4968034
什么是DOI,文献DOI怎么找? 2678871
邀请新用户注册赠送积分活动 1623127
关于科研通互助平台的介绍 1579506